Want to see IN:BAFNAPH full AI Analyst Report?
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹95.00 - ₹322.50
Previous CloseN/A
Volume2.58K
Average Volume (3M)5.99K
Market Cap
₹7.63B
Enterprise Value₹3.03K
Total Cash (Recent Filing)₹20.25M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)96.4
Beta0.71
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.93%
Share Statistics
EPS (TTM)3.29
Shares Outstanding23,656,336
10 Day Avg. Volume1,532
30 Day Avg. Volume5,988
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue ExpansionRevenue growth across the 2021–2026 period indicates the formulation business has expanded its scale over multiple years, supporting broader commercial reach and a larger base for future operating leverage. The recent slowdown means momentum is uneven, but the cumulative trend remains a fundamental strength.
Sound Balance-sheet FoundationA steadily building equity base and moderate leverage provide a financial foundation for ongoing pharmaceutical operations and investment. Although debt has risen recently, the combination of expanding assets and meaningful equity improves resilience and leaves more capacity to manage obligations than a highly leveraged structure would.
2026 Earnings RecoveryThe sharp net-income rebound in 2026 shows that the company can restore earnings after the margin compression seen in 2024–2025. If supported by operating execution, this recovery can improve internal funding capacity and reinforce the economics of the established formulation portfolio, though consistency remains important.
Bears Say
Persistently Weak Free Cash FlowNegative free cash flow in five of the reported years shows that accounting profitability has not consistently translated into cash available for reinvestment or debt reduction. Persistent cash absorption can reduce financial flexibility and increase reliance on external funding, making cash conversion a material constraint over the coming quarters.
Volatile Profit MarginsMargins were very strong in 2022–2023 but compressed materially in 2024–2025, demonstrating that earnings power is not yet stable across the cycle. Such volatility makes future profits harder to plan, can weaken the benefits of revenue scale, and may limit the predictability of internally generated cash.
Rising Debt TrendDebt has increased in recent years, notably into 2026, making leverage the main balance-sheet risk identified in the pack. Even with a meaningful equity base and expanding assets, continued debt growth could raise fixed obligations and constrain capital allocation if earnings or cash generation weaken.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹95.00 and its highest was ₹322.50 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹7.63B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is Nov 12, 2026 which is in 52 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on Aug 11, 2026. The company reported ₹0.032 earnings per share for the quarter.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of 1.93%. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹0.032 in its last earnings report. Following the earnings report the stock price went down -1.987%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences LLP.
Technical Analysis
Hikal Limited
―
Kilitch Drugs (India) Limited
―
Sanofi India Limited
―
Supriya Lifescience Limited
―
Wockhardt Limited
―